Poster
Jun 3, 2024
ASCO-24: AI-Enabled Digital Test to Predict Disease Recurrence for Patients with Early-Stage Invasive Breast Cancer Demonstrates Good Performance in a MammaPrint Low-risk Cohort from the Netherlands with a Median 6-year Follow-Up
See More
Jun 3, 2024
ASCO-24: AI-Enabled Digital Test to Predict Disease Recurrence for Patients with Early-Stage Invasive Breast Cancer Demonstrates Good Performance in a MammaPrint Low-risk Cohort from the Netherlands with a Median 6-year Follow-Up
See More
Media Coverage
May 31, 2024
360Dx Newsletter: Cota, PreciseDx, Baptist Health South Florida to Assess Invasive Breast Cancer Recurrence Test
See More
May 31, 2024
360Dx Newsletter: Cota, PreciseDx, Baptist Health South Florida to Assess Invasive Breast Cancer Recurrence Test
See More
Media Coverage
May 31, 2024
COTA, Baptist Health South Florida, PreciseDx collaborate on AI-based test for IBC recurrence
See More
May 31, 2024
COTA, Baptist Health South Florida, PreciseDx collaborate on AI-based test for IBC recurrence
See More
Media Coverage
May 31, 2024
Cota, PreciseDx, Baptist Health South Florida to Assess Invasive Breast Cancer Recurrence Test
See More
May 31, 2024
Cota, PreciseDx, Baptist Health South Florida to Assess Invasive Breast Cancer Recurrence Test
See More
Media Coverage
May 30, 2024
COTA, Baptist Health and PreciseDx collaborate on breast cancer test
See More
May 30, 2024
COTA, Baptist Health and PreciseDx collaborate on breast cancer test
See More
Media Coverage
May 30, 2024
Cota, PreciseDx, Baptist Health South Florida to Assess Invasive Breast Cancer Recurrence Test
See More
May 30, 2024
Cota, PreciseDx, Baptist Health South Florida to Assess Invasive Breast Cancer Recurrence Test
See More
May 29, 2024
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
See More
May 29, 2024
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
See More
Media Coverage
May 29, 2024
New AI Test Aims to Improve Breast Cancer Recurrence Prediction: COTA, PreciseDx, and Baptist Health South Florida Collaborate
See More
May 29, 2024
New AI Test Aims to Improve Breast Cancer Recurrence Prediction: COTA, PreciseDx, and Baptist Health South Florida Collaborate
See More
Media Coverage
May 29, 2024
Cota, Baptist Health South Florida, And Precisedx Announce Collaboration On The AI-enabled Breast Cancer Recurrence Risk Assessment
See More
May 29, 2024
Cota, Baptist Health South Florida, And Precisedx Announce Collaboration On The AI-enabled Breast Cancer Recurrence Risk Assessment
See More
No results.
Contact us today to learn more about PreciseBreast.
